1 

Resolution No. 10/23-1 

 

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES 

VACCINES FOR CHILDREN PROGRAM 

VACCINES TO PREVENT MENINGOCOCCAL DISEASE 

 

The purpose of this resolution is to update the resolution to add a new component to the 

VFC resolution to reflect a newly available combination meningococcal vaccine that can 

be used to prevent meningococcal disease attributable to serogroups A, C, W, Y and B, and 

to make minor updates to the existing components of the resolution (MenACWY component 

and MenB component).

VFC resolution 6/20-1 is repealed and replaced by the following: 

Meningococcal Conjugate Vaccines (MenACWY) 

Eligible Groups 

• Children aged 2 months through 10 years who are at increased risk for meningococcal disease

attributable to serogroups A, C, W, and Y, including: 

o

o

o

o

o

o

Children who have persistent complement component deficiencies (including inherited or 

chronic deficiencies in C3, C5-C9, properdin, factor H, or factor D) 

Children taking a complement inhibitor (e.g., eculizumab [Soliris], ravulizumab 

[Ultomiris]) 

Children who have anatomic or functional asplenia, including sickle cell disease 

Children infected with human immunodeficiency virus (HIV)

Children traveling to or residing in countries in which meningococcal disease is 

hyperendemic or epidemic, particularly if contact with local population will be prolonged 

Children identified to be at increased risk because of a meningococcal disease outbreak 

attributable to serogroups A, C, W, or Y 

• All children aged 11 through 18 years 
2

Recommended Vaccination Schedule and Intervals 

The table below lists meningococcal conjugate vaccines currently available to prevent 

meningococcal disease attributable to serogroups A, C, W, and Y. 

Vaccine 

Type 

Brand

(1)

Age 

indication 

(pediatric)

Children at increased risk

Children not at 

increased risk

2m through 23m

2y through 

18y Booster Doses

Primary: 1 dose at age 

11-12y (or 13-18y) if 

not vaccinated 

previously)

Booster: 1 dose at age 

16 (if vaccinated at 11-

12y) or 1 dose at 16-

18y (if vaccinated at 

13-15y)

MenACWY-CRM 

(lyophilized)

Menveo 

Two-Vial 

2m - 18y Initiating at 2m: 4 

doses, at 2, 4, 6, 

and 12 m

Initiating at 7-

23m: 2 doses, 12 

wks apart

For children 

with 

persistent 

complement 

deficiencies, 

complement 

inhibitor use 

(2), 

functional 

or anatomic 

asplenia, or 

HIV: 2 

doses, ≥8

wks apart

Other 

children at 

increased 

risk: 1 dose

For children who 

remain at 

increased risk and 

completed the 

primary dose or 

series at age:

<7y: additional 

dose 3 yrs after 

primary; boosters 

should be 

repeated every 5 y

>= 7 y: additional 

dose 5 yrs after 

primary; boosters 

should be 

repeated every 5 y

MenACWY-CRM 

(liquid)

Menveo 

One-Vial

10y – 18y Not indicated

MenACWY-TTMenQuadfi 2y - 18y Not indicated

(1) Use of brand names is not meant to preclude the use of other comparable US licensed vaccines

(2) Includes eculizumab (Soliris) and ravulizumab (Ultomiris) 

Recommended schedules and intervals for meningococcal conjugate vaccines can be found at the 

following links: 

• http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf

• http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6324a2.htm

• https://www.cdc.gov/mmwr/volumes/65/wr/mm6543a3.htm

Recommended dosage Refer to product package inserts. 

Contraindications and Precautions

Contraindications and Precautions can be found in the package inserts available at 

https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states 
3

Serogroup B Meningococcal Vaccines (MenB)

Eligible groups 

• Children aged 10 through 18 years at increased risk for serogroup B meningococcal disease, 

including: 

o

o

o

o

Children who have persistent complement component deficiencies (including 

inherited or chronic deficiencies in C3, C5-C9, properdin, factor H, or factor D) 

Children taking a complement inhibitor (e.g., eculizumab [Soliris], ravulizumab 

[Ultomiris]) 

Children who have anatomic or functional asplenia, including sickle cell disease

Children identified to be at increased risk because of a meningococcal disease 

outbreak attributable to serogroup B

• Children aged 16 through18 years who are not at increased risk for serogroup B 

meningococcal disease may also be vaccinated when shared clinical decision-making favors 

administration of MenB

Recommended Vaccination Schedule and Intervals

Vaccine (1),

(3)

Age 

Group

Dosing Schedule (Primary 

Series)

Dosing Schedule (Booster Dose)

MenB-4C

(Bexsero, 

GSK) 

10–18 

years

Two doses, at least one 

month apart (0 and ≥1 

month schedule)

-For children at increased risk due to complement 

deficiency, complement inhibitor use, or functional or 

anatomic asplenia: 

A booster dose is recommended if it has been at 

least one year since primary series; repeat every 2-

3 years as long as risk remains.

-For children at increased risk due to a serogroup B 

outbreak:

Booster dose recommended if it has been at least 

one year since primary series. If recommended by 

public health officials, booster dose may be given if 

it has been at least 6 months since primary series. 

-Booster doses are not recommended for adolescents 

who are not at increased risk for meningococcal 

disease.

MenB-FHbp

(Trumenba, 

Pfizer)

10–18 

years

-Persons at increased risk 

for meningococcal disease 

including during serogroup 

B outbreaks: Three doses (0, 

1-2, and 6 month schedule)

-Adolescents who are not at 

increased risk for 

meningococcal disease: Two 

doses (0, 6 months) (2)

(1) Use of brand names is not meant to preclude the use of other comparable US licensed vaccines. 

(2) If the second dose is administered earlier than 6 months after the first dose, a third dose should 

be administered at least 4 months after the second dose. 

(3) MenB vaccines are not interchangeable by manufacturer. Administration of a B component 

vaccine (MenB or MenACWY-TT-MenB-FHbp) requires that subsequent B component vaccine

doses be from the same manufacturer.

Recommended dosage 

Refer to product package inserts. 

Contraindications and Precautions

Contraindications and Precautions can be found in the package inserts available at 

https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states 
4

Combined Pentavalent Serogroup A, C, W, Y, and B Meningococcal 

(MenACWY-MenB) Vaccine

Eligible groups 

• Children who are indicated to receive MenACYW and Men B vaccines, including: 

o

o

Children aged 10 through 18 years who are at increased risk for meningococcal 

disease attributable to serogroups A, C, W, Y, and B, including: 

 Children who have persistent complement component deficiencies 

(including inherited or chronic deficiencies in C3, C5-C9, properdin, factor 

H, or factor D)

 Children taking a complement inhibitor (e.g., eculizumab [Soliris], 

ravulizumab [Ultomiris])

 Children who have anatomic or functional asplenia, including sickle cell 

disease

Children aged 16 through 18 years for whom both MenACWY and MenB are 

indicated to be given at the same time and shared clinical decision-making favors 

administration of MenB vaccine.

Recommended Vaccination Schedule and Intervals 

The table below displays dosing schedules for MenACWY-TT-MenB-FHbp (Penbraya) (1).

Children at Increased Risk

Dosing Schedule Children not at Increased Risk

(Primary Series) 

Dosing Schedule 

(Boosters)

For children with persistent 

complement deficiencies, 

complement inhibitor use (2), or 

functional or anatomic asplenia 

who are due for both 

MenACWY and MenB 

vaccination: 1 dose may be 

given in lieu of the first dose of 

MenACWY and MenB-FHbp 

If subsequent doses of 

MenACWY and MenB-FHbp (3) 

are indicated less than 6 months 

after the first dose, the vaccines 

should be given separately 

according to the MenACWY and 

MenB tables above. 

For subsequent 

doses, where 

both MenACWY 

and MenB are 

indicated and at 

least 6 months 

have passed 

since 

administration of 

a previous dose 

of MenACWY-TTMenB-FHbp, 

MenACWY-TTMenB-FHbp may 

be used.

Initial dose: may be given in lieu of 

MenACWY and MenB when both vaccines 

are indicated in the same visit (e.g., age 16 

years) and shared clinical decision-making 

favors administration of MenB

Second dose: 

The MenB series should then be completed 

with monovalent MenB-FHbp. 

(1) Use of brand names is not meant to preclude the use of other comparable US licensed vaccines

(2) Includes eculizumab (Soliris) and ravulizumab (Ultomiris) 

(3) MenB vaccines are not interchangeable by manufacturer. Administration of a B component vaccine 

(MenB or MenACWY-TT-MenB-FHbp) requires that subsequent B component vaccine doses be from 

the same manufacturer. 
5 

Recommended dosage Refer to product package inserts. 

Contraindications and Precautions

Contraindications and Precautions can be found in the package inserts available at 

https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states 

[If an ACIP recommendation or notice regarding meningococcal vaccination is published within 6 

months following this resolution, the relevant language above (except in the eligible groups sections) 

will be replaced with the language in the recommendation and incorporated by reference to the 

publication URL.] 

 

Adopted and Effective: October 25, 2023 

This document can be found on the CDC website at: 

https://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html